Table 2.
Patient and tumor characteristics
| Overall | OX | IRI | p-value | |
|---|---|---|---|---|
| Number of patients [n] | 32 | 20 | 12 | |
| I. Patient characteristics | ||||
| Mean age (range) [y] | 54 (20-68) | 53 (20-68) | 54 (42-66) | 0.842 |
| Sex [n] - male | 14 (43.8%) | 9 (45.0%) | 5 (41.7%) | |
| - female | 18 (56.3%) | 11 (55.0%) | 7 (52.8%) | 1.000 |
| ASA score [n] | ||||
| - ASA I | 3 (9.4%) | 2 (10.0%) | 1 (8.3%) | 1.000 |
| - ASA II | 23 (71.9%) | 14 (70.0%) | 9 (75.0%) | 1.000 |
| - ASA III | 6 (18.8%) | 4 (20.0%) | 2 (16.7%) | 1.000 |
| II. Localization of primary tumor | ||||
| Appendix | 11 (34.4%) | 9 (45.0%) | 2 (16.7%) | 0.139 |
| Colon | 7 (21.9%) | 2 (10.0%) | 5 (41.7%) | 0.073 |
| Sigma | 10 (31.3%) | 7 (35.0%) | 3 (25.0%) | 0.702 |
| Rectum | 4 (12.5%) | 2 (10.0%) | 2 (16.7%) | 0.620 |
| III. Initial TNM classification | ||||
| T2 | 1* (3.2%) | 1 (5.0%) | 0** | 1.000 |
| T3 | 10* (32.3%) | 6 (30.0%) | 4** (36.4%) | 1.000 |
| T4 | 20* (64.5%) | 13 (65.0%) | 7** (63.7%) | 1.000 |
| N0 | 16* (51.6%) | 13 (65.0%) | 3** (27.3%) | 0.066 |
| N1 | 5* (16.1%) | 2 (10.0%) | 3** (27.3%) | 0.317 |
| N2 | 10* (32.3%) | 5 (25.0%) | 5** (45.5%) | 0.423 |
| M1 | 22 (68.8%) | 14 (70.0%) | 8 (66.7%) | 1.000 |
| G1 | 5 (15.6%) | 5 (25.0%) | 0 | 0.130 |
| G2 | 11 (34.4%) | 7 (35.0%) | 4 (33.3%) | 1.000 |
| G3 | 16 (50.0%) | 8 (40.0%) | 8 (66.7%) | 0.273 |
| IV. Further tumor characteristics | ||||
| Mean PCI (range) | 13 (2-28) | 13 (4-28) | 12 (2-28) | 0.630 |
| Synchronous PM | 16 (50.0%) | 10 (50.0%) | 6 (50.0%) | 1.000 |
| Metachronous PM | 10 (31.3%) | 6 (30.0%) | 4 (33.3%) | 1.000 |
| Recurrent disease | 6 (18.8%) | 4 (20.0%) | 2 (16.7%) | 1.000 |
| Liver metastasis | 4 (12.5%) | 1 (5.0%) | 3 (25.0%) | 0.271 |
| V. Medical history | ||||
| Previous abdominal surgery | 14 (43.8%) | 9 (45.0%) | 5 (41.7%) | 1.000 |
| Previous oncologic surgery | 24 (75.0%) | 14 (70.0%) | 10 (83.3%) | 0.676 |
| Previous CRS and HIPEC | 5 (15.6%) | 3 (15.0%) | 2 (16.7%) | 1.000 |
| Previous chemotherapy | 28 (87.5%) | 16 (80.0%) | 12 (100%) | 0.271 |
| Previous systemic oxaliplatin | 17 (53.1%) | 11 (55.0%) | 6 (50%) | 1.000 |
*n = 31, **n = 11.